AAM Applauds Q1/Q2 House Bill Passage
Cuts red tape, brings patient faster access to lower-cost medicines WASHINGTON (December 1, 2025) — The Association for Accessible Medicines today applauded passage of Q1/Q2
Cuts red tape, brings patient faster access to lower-cost medicines WASHINGTON (December 1, 2025) — The Association for Accessible Medicines today applauded passage of Q1/Q2
The final day of GRx+Biosims was a rewarding day of excitement for all participants. If Day 1 was about passion and purpose, and Day 2
FDA Commissioner Makary joined AAM’s GRx+Biosims 2025 conference today WASHINGTON (October 29, 2025) — The Association for Accessible Medicines, the trade association representing America’s manufacturers
If Day 1 was about rekindling purpose, Day 2 was about putting it into motion. The morning opened with the same buzz of momentum with
The first day of the 2025 GRx+Biosims Conference set an energetic tone for the days ahead full of optimism, urgency, and shared purpose. With a
Generic Pharmaceutical Trade Group Steps in to Protect Patient Access To Affordable Generic Drugs WASHINGTON (October 23, 2025) — The Association for Accessible Medicines, the trade
New Florida facility will create hundreds of new jobs and produce 25 critical respiratory medicines and inhalers WASHINGTON (October 7, 2025) — The Association for Accessible
Generic and biosimilar medicines save significantly more money for patients and plans than government price controls WASHINGTON (October 7, 2025) — The Association for Accessible Medicines
Will cut red tape, bring lower-cost medicines to patients faster WASHINGTON, DC (September 18, 2025) – The Association for Accessible Medicines today thanked the House
By John Murphy III, President & CEO, AAM In 2024, generic and biosimilar medicines comprised 90 percent of all prescriptions filled, but only 12 percent
AAM analysis shows tactics used by brand drug companies to deny market entry to life-saving lower-cost generic medicines and outlines solutions WASHINGTON, DC (September 4,
90% of all prescriptions filled, yet only 12% of the spending, affordable medicines face severe sustainability challenges in the U.S. WASHINGTON, DC (September 3, 2025)
